Michael R. Harrison, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Michael R. Harrison, MD

Professor, Department of Surgery (Pediatric Surgery), UCSF

Phone: (415) 476-2538 (appts)
Box 0570, UCSF
San Francisco, CA 94143-0570

View on UCSF Profiles

Research Summary

As founding director of UCSF's Fetal Treatment Center, Harrison is internationally renowned for his expertise and innovation in pediatric and fetal surgery. Widely regarded as the "father of fetal surgery," Harrison, over the last three decades, concentrated his lab efforts to establish the developmental pathophysiology of correctable birth defects in animal models, and develop and test techniques for fetal intervention (including maternal-fetal anesthesia), prior to clinical application. Now, a decade into the new century, the pioneering spirit continues and manifests in a new direction of innovation-i.e., original thought combined with the first presentation of work that leads to a milestone in the advancement of surgical care. Harrison's current research focuses on pediatric orphan device development, particularly devices employing the use of magnetic force. His most recent work has earned him one of three prestigious stimulus grants awarded by the FDA to fund a pediatric device consortium at UCSF.

Over the last six years, the Harrison lab has explored the use of magnetic force to correct a variety of problems and deformities. They began with the Magnetic Mini-Mover Procedure (3MP) to correct pectus excavatum in children, and tested the Magnimplant device in an FDA-sponsored trial with an FDA-approved IDE. In addition to the Magnetic Mini-Mover, they are continuing to develop and test:

- The Magnamosis device which uses specially designed magnets to create a secure compression anastomosis between any two pieces of intestine

- A magnetic internal-control contraction device to assist in laparoscopic surgery

- The Robo-Implant device, which uses magnetic coupling to activate and lengthen and shorten an internal growing rod for treatment of scoliosis and for limb lengthening.

In the course of developing and testing these magnetic implant treatments, the Harrison Lab most recently began considering the use of magnetic force for the treatment of obstructive sleep apnea. The concept is simple. In the same way that they implant a titanium-encased rare earth magnet on the sternum in patients with pectus excavatum and then, later, the patients use an external magnet orthotic device to gradually pull the 'sunken chest' out, Harrison et al are considering the possibility of implanting a similar magnet on the hyoid bone and letting the patient use an external orthotic magnetic device to pull the hyoid forward and open the airway when sleeping. With this approach the patient is unaffected while awake during the day and the implanted device is essentially invisible.

Under the auspices of the UCSF Pediatric Device Consortium, the mission of the Harrison Lab is to facilitate the development, production, and distribution of pediatric medical devices by:

- Encouraging innovation and connecting qualified individuals with pediatric device ideas with potential manufacturers

- Mentoring and managing pediatric device projects through the development process, including product identification, prototype design, device development, and marketing

- Connecting innovators and physicians to existing Federal and non-Federal resources

- Assessing the scientific and medical merit of proposed pediatric device projects

- Providing assistance and advice as needed on business development, personnel training, prototype development, and post-marketing needs

Selected Publications

  1. What Should We Tell Patients About Physical Activity After a Prostate Cancer Diagnosis? Oncology (Williston Park). 2015 Sep; 29(9).
    View on PubMed
  2. Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice. J Oncol Pract. 2015 Nov; 11(6):491-7.
    View on PubMed
  3. Impedance sensing device for monitoring ulcer healing in human patients. Conf Proc IEEE Eng Med Biol Soc. 2015 Aug; 2015:5130-3.
    View on PubMed
  4. Optimizing the efficiency and quality of sipuleucel-T delivery in an academic institution. Clin J Oncol Nurs. 2015 Jun 1; 19(3):297-303.
    View on PubMed
  5. Chemokine-guided angiogenesis directs coronary vasculature formation in zebrafish. Dev Cell. 2015 May 26; 33(4):442-54.
    View on PubMed
  6. Impedance sensing device enables early detection of pressure ulcers in vivo. Nat Commun. 2015; 6:6575.
    View on PubMed
  7. Reversal of PSA progression on abiraterone acetate through the administration with food in men with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2015 Jun; 18(2):161-6.
    View on PubMed
  8. Challenges and climate of business environment and resources to support pediatric device development. Semin Pediatr Surg. 2015 Jun; 24(3):107-11.
    View on PubMed
  9. Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2015 Aug; 13(4):392-9.
    View on PubMed
  10. Profiles in surgical research: Michael R. Harrison, MD, FACS. Bull Am Coll Surg. 2015 Jan; 100(1):35-40.
    View on PubMed
  11. Deferred systemic therapy in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer. 2015 Jun; 13(3):e159-66.
    View on PubMed
  12. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol. 2015 May 1; 33(13):1430-7.
    View on PubMed
  13. Shear stress-activated Wnt-angiopoietin-2 signaling recapitulates vascular repair in zebrafish embryos. Arterioscler Thromb Vasc Biol. 2014 Oct; 34(10):2268-75.
    View on PubMed
  14. Use of "Real-World" data to describe adverse events during the treatment of metastatic renal cell carcinoma in routine clinical practice. Med Oncol. 2014 Sep; 31(9):156.
    View on PubMed
  15. Miniaturizing RFID for magnamosis. Conf Proc IEEE Eng Med Biol Soc. 2014 Aug; 2014:638-41.
    View on PubMed
  16. Treatment selection in metastatic renal cell carcinoma: more confusion or a path forward? Clin Adv Hematol Oncol. 2014 Mar; 12(3):163-71.
    View on PubMed
  17. Cardiac regeneration in model organisms. Curr Treat Options Cardiovasc Med. 2014 Mar; 16(3):288.
    View on PubMed
  18. Burden of disease matters when it comes to systemic therapy for prostate cancer. Eur Urol. 2015 Mar; 67(3):448-50.
    View on PubMed
  19. Exercise as treatment for androgen deprivation therapy-associated physical dysfunction: ready for prime time? Eur Urol. 2014 May; 65(5):873-4.
    View on PubMed
  20. Real-world outcomes in metastatic renal cell carcinoma: insights from a Joint Community-Academic Registry. J Oncol Pract. 2014 Mar; 10(2):e63-72.
    View on PubMed

Go to UCSF Profiles, powered by CTSI